NCT03405792: Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
- State
- Under way
- Phase
- Phase 2
- People
- 40 taking part
- Started
- 23 Feb 2018
- Primary completion
- 26 Nov 2022
- Arms
- Optune System combined with Temozolomide (TMZ) + Pembrolizumab
- Results
- Posted on the registry
- 23 Jan 2018: Trial registered
- 23 Feb 2018: Trial started
- 15 Apr 2024: Trial results posted